Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages S249-S257

  Andreana, Lorenzo ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; Early hepatocellular carcinoma; Neo adjuvant therapy; Prevention; Recurrence

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PEGINTERFERON; PLACEBO; POLYPRENOIC ACID; PRAVASTATIN; RAPAMYCIN; RETINOID; RIBAVIRIN; SORAFENIB; YTTRIUM 90; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ADAPTIVE IMMUNITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER PREVENTION; CANCER RECURRENCE; CHEMOPROPHYLAXIS; CLINICAL CLASSIFICATION; CLINICAL TRIAL; EARLY CANCER; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LOCAL METASTASIS; MOLECULARLY TARGETED THERAPY; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR VOLUME; ABLATION THERAPY; ADJUVANT THERAPY; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

ABLATION TECHNIQUES; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 77953704458     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60513-0     Document Type: Article

References (67)

1. Llovet JM, Bruix J Novel advancements in the management of hepato-cellular carcinoma in 2008. J Hepatol 2008, 48(Suppl l):S20-S37.
2. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepa-tology 2005, 42(5):1208-1236.
3. Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology 1986, 90(2):289-298.
4. Tang ZY, Yu YQ, Zhou XD, Yang BH, Ma ZC, Lin ZY Subclinical hepatocellular carcinoma: an analysis of 391 patients. J Surg Oncol Suppl 1993, 3:55-58.
5. Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998, 28(5):1241-1246.
6. Llovet JM, Brú C, Bruix J Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338.
7. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(1l):693-699.
8. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009, 49(2):658-664. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia.
9. Cottone M, Virdone R, Fusco G, et al. Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology 1989, 96(6):1566-1571.
10. Llovet JM, Burroughs A, Bruix J Hepatocellular carcinoma. Lancet 2003, 362(9399):1907-1917.
11. Beaugrand M, N'kontchou G, Seror O, et al. Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):201-211.
12. Jonas S, Bechstein WO, Steinmüller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33(5):1080-1086.
13. Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996, 111(3):720-726.
14. Llovet JM, Schwartz M, Mazzaferro V Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):181-200.
15. Nakashima O, Kojiro M Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis?. A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg 2001, 8(5):404-409.
16. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000, 89(3):500-507.
17. Cucchetti A, Piscaglia F, Caturelli E, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009, 16(2):413-422.
18. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38(2):200-207.
19. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998, 27(6):1572-1577.
20. Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009, 137(3):850-855.
21. Paterlini P Clinical implications of spontaneous and iatrogenic dissemination of tumor cells in patients with primary liver cancer. C R Seances Soc Biol Fil 1998, 192(2):283-288.
22. Plessier A, Codes L, Consigny Y, et al. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004, 10(2 Suppl l):S86-S90.
23. Nishie A, Yoshimitsu K, Irie H, et al. Radiological detectability of minute hepatic venous invasion in hepatocellular carcinoma. Eur J Radiol 2009, 70(3):517-524. Epub 2008 Apr 11.
24. Kim H, Park MS, Choi JY, et al. Can microvessel invasion of hepatocellular carcinoma be predicted by pre-operative MRI?. Eur Radiol 2009, 19(7):1744-1751.
25. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologie grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005, 11(9):1086-1092.
26. Kim BK, Han KH, Park YN, et al. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol 2008, 97(3):246-252.
27. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359(19):1995-2004.
28. Yoshioka S, Takemasa I, Nagano H, et al. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer 2009, 45:881-889.
29. Kamiyama T, Nakanishi K, Yokoo H, et al. The impact of anatomical resection for hepatocellular carcinoma that meets the Milan criteria. J Surg Oncol 2010, 101(1):54-60.
30. Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol 2010, 52:380-388.
31. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?. Hepatology 2008, 47(1):82-89.
32. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006, 243(3):321-328.
33. Lii MD, Kuang M, Liang LJ, et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006, 86(12):801-805.
34. Huang GT, Lee PH, Tsang YM, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005, 242(1):36-42.
35. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10(1):35-43.
36. Marelli L, Grasso A, Pleguezuelo M, et al. Tumour size and differentiation in predicting recurrence of hepatocellular carcinoma after liver transplantation: external validation of a new prognostic score. Ann Surg Oncol 2008, 15(12):3503-3511.
37. Samuel M, Chow PK, Chan Shih-Yen E, et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009 Jan 21, (1). CD001199.
38. Lygidakis NJ, Pothoulakis J, Konstantinidou AE, et al. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 1995, 15(2):543-550.
39. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999, 353(9155):797-801.
40. Mathurin P, Raynard B, Dharancy S, et al. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 2003, 17(10):1247-1261.
41. Lau WY, Lai EC, Leung TW, et al. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008, 247(1):43-48.
42. Marelli L, Stigliano R, Triantes C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective?. A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007, 30(1):6-25.
43. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 micro-spheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006, 94(7):572-586.
44. Chen MS, Zhang YJ, Li JQ, et al. Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency ablation alone for small hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2005, 27(10):623-625.
45. Koda M, Murawaki Y, Mitsuda A, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 2001, 92(6):1516-1524.
46. Akamatsu M, Yoshida H, Obi S, et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 2004, 24(6):625-629.
47. Marelli L, Stigliano R, Triantes C, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006, 32(8):594-606.
48. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003, 9(6):557-563.
49. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004, 240(5):900-909.
50. Stigliano R, Burroughs AK Should we biopsy each liver mass suspicious for HCC before liver transplantation? - no, please don't. J Hepatol 2005, 43(4):563-568.
51. Stigliano R, Marelli L, Yu D, et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome?. Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007, 33(5):437-447.
52. Cheaito A, Yoshida A, Kim DY, et al. Effect of RFA and TACE on recurrence of hepatocellular carcinoma after liver transplantation 8 year experience with 145 patients. Hepatology 2009, 50(Suppl 4):601A. Abstract 627.
53. Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003, 238(6):885-892.
54. Sala M, Fuster J, Llovet JM, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004, 10(10):1294-1300.
55. Monaco AP The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009, 87(2):157-163.
56. http://www.clinicaltrials.gov/ct2/show/NCT00355862.
57. Mute Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334(24):1561-1567.
58. Takai K, Okuno M, Yasuda I, et al. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 2005, 48(1):39-45.
59. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009, 136(5):1601-1608.
60. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001, 84(7):886-891.
61. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359(23):2429-2441.
62. Craxì A, Cammà C Prevention of hepatocellular carcinoma. Clin Liver Dis 2005, 9(2):329-346.
63. Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009, 96(9):975-981.
64. Singal AK, Anand BS Interferon in the prevention of HCC recurrence after resection of HCV associated HCC: a meta-analysis. Hepatology 2009, 50(Suppl 4):557A-5578. Abstract 529.
65. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000, 356(9232):802-807.
66. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390.
67. http://www.clinicaltreials.gov/ct2/show/NCT00692770.